联合 p53 和 Bcl2 免疫表型在越南浸润性乳腺癌预后中的作用：单中心回顾性分析。

Combined p53 and Bcl2 Immunophenotypes in Prognosis of Vietnamese Invasive Breast Carcinoma: A Single Institutional Retrospective Analysis.

机构信息

Department of Quan Su Pathology, National Cancer Hospital, Hanoi, Vietnam.

Department of Clinical Pathology, Hanoi Medical University, Hanoi, Vietnam.

出版信息

Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820983081. doi: 10.1177/1533033820983081.

DOI:10.1177/1533033820983081

PMID:33357134

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7780323/

Abstract

BACKGROUND

Aberrant of p53 and Bcl2 genes cause changes in the quantity and quality of their proteins and contribute to the pathogenesis of some cancer types including breast cancer. Expression of p53 and Bcl2 were associated to adverse clinical outcomes in breast cancer.

PURPOSE

To predict the survival outcomes of invasive breast cancer in Vietnam, using immunohistochemical expression of p53, Bcl2 proteins.

METHODS

The current study was conducted on 526 breast cancer patients who had surgical operations, but had not received neo-adjuvant chemotherapy, from 2011 to 2014. The clinicopathological characteristics were recorded. Immunohistochemical staining was performed on p53, Bcl2 markers. Expression of p53 and Bcl2 were paired into different immunophenotypes for analysis with clinicopathological characteristics and survival. All breast cancer patients' survival were analyzed by using Kaplan-Meier and Log-Rank models.

RESULTS

The presence of p53 protein was detected in 44.1%. Positive p53, and p53+Bcl2- immunophenotype were significantly associated with poorer prognostic features. In contrast, the positive Bcl2 protein accounted on 57.6%, and combination of p53-Bcl2+ were strong correlated with better clinicopathological parameters. Bcl2 positivity was observed in higher than the negative Bcl2 in the five-year OS (Overall survival) proportion (91.2 vs 79.4%, respectively) (p < 0.05). Multivariate analysis revealed that the expression of p53, Bcl2 or combinations of these 2 proteins was no longer remained as an independent prognostic variable.

CONCLUSION

The Bcl2 positivity had a distinct OS and DFS (Disease free survival). The expression of p53 and Bcl2 are inversely correlated to clinical outcomes in breast cancer.

摘要

背景

p53 和 Bcl2 基因的异常会导致其蛋白数量和质量的改变，并促成一些癌症类型的发病机制，包括乳腺癌。p53 和 Bcl2 的表达与乳腺癌的不良临床结局相关。

目的

使用 p53、Bcl2 蛋白的免疫组织化学表达来预测越南浸润性乳腺癌的生存结局。

方法

本研究对 2011 年至 2014 年间接受手术但未接受新辅助化疗的 526 例乳腺癌患者进行了研究。记录了临床病理特征。对 p53、Bcl2 标志物进行了免疫组织化学染色。将 p53 和 Bcl2 的表达进行配对，分析与临床病理特征和生存的关系。使用 Kaplan-Meier 和 Log-Rank 模型对所有乳腺癌患者的生存情况进行分析。

结果

p53 蛋白的存在率为 44.1%。阳性 p53 和 p53+Bcl2-免疫表型与预后不良的特征显著相关。相比之下，阳性 Bcl2 蛋白的比例为 57.6%，p53-Bcl2+的组合与更好的临床病理参数密切相关。Bcl2 阳性在五年 OS（总体生存）比例（分别为 91.2%和 79.4%）中高于 Bcl2 阴性（p<0.05）。多变量分析显示，p53、Bcl2 或这两种蛋白的组合表达不再是独立的预后变量。